P06 OFATUMUMAB FOR B CELL DEPLETION THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO ARE INTOLERANT OF RITUXIMAB
Main Authors: | S. McAdoo, S. Masoud, R. Bedi, T. Cairns, L. Lightstone |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-11-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024916300912 |
Similar Items
-
Rituximab in the management of systemic lupus erythematosus
by: Adrian Levitsky, et al.
Published: (2013-06-01) -
Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01) -
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
by: Wiesik-Szewczyk E, et al.
Published: (2012-09-01) -
Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy
by: Kelly W Burak, et al.
Published: (2013-01-01) -
Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
by: López Longo J, et al.
Published: (2010-11-01)